CNBC's Jim Cramer talks about small-cap biotech company Kura Oncology and analyzes the company's stock performance. Got a confidential news tip? We want to hear from you. Sign up for free newsletters ...
In the case of Kung Fu Tea, there are three kinds of drinks, cups based on Chikorita, Tepig, and Totodile. It is also possible to get a straw cap that looks like Pikachu with your purchase. Each drink ...
The average one-year price target for Kura Oncology (NasdaqGS:KURA) has been revised to $31.53 / share. This is an increase of 14.48% from the prior estimate of $27.54 dated November 7, 2025. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It's targeting record new store ...
Nov 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Kura Oncology (KURA.O), opens new tab and Japanese partner Kyowa Kirin's (4151.T), opens new tab once-daily pill, Komzifti ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has ...
Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia. On Thursday, the FDA signed off ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Our robot overlords are ready to take over dining. The Des Moines metro is about to join the conveyor belt sushi restaurant trend. Kura Revolving Sushi Bar plans to open at Jordan Creek Town Center in ...
An opening date has been announced for Modesto’s newest sushi conveyor-belt restaurant. Kura Revolving Sushi Bar will open in Vintage Faire Mall at 3401 Dale Road on Friday, Nov. 14. The lower-level ...
Fintel reports that on October 20, 2025, JMP Securities reiterated coverage of Kura Oncology (NasdaqGS:KURA) with a Market Outperform recommendation. Analyst Price Forecast Suggests 175.68% Upside As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results